Reducing Radiation Retinopathy Risk After Uveal Melanoma Treatment
Overview
Radiation retinopathy is the leading cause of vision loss following plaque brachytherapy for choroidal melanoma, typically manifesting 6 months to 3 years post-treatment. Emerging strategies including radiation dose reduction, genetic risk stratification, novel systemic therapies, and prophylactic intravitreal treatments show promise in preserving vision without compromising tumor control.
Background
Radiation retinopathy presents with clinical features similar to diabetic retinopathy and is challenging to manage once established, often resulting in significant vision loss. Standard treatment involves an 85 Gy radiation dose to control tumors, but this can damage retinal tissue. Current management mirrors diabetic retinopathy treatments such as anti-VEGF injections and panretinal photocoagulation. New approaches aim to prevent retinopathy by modifying radiation protocols, leveraging tumor genetics, and introducing systemic and prophylactic therapies.
Data Highlights
| Parameter | Findings |
|---|---|
| Radiation Dose | Standard 85 Gy vs Reduced 63 Gy to lower retinopathy severity |
| Visual Outcome with Prophylactic Bevacizumab | 4-year median visual acuity 20/70 vs counting fingers in controls |
| Incidence of Vision Loss at 3 Years (Early Studies) | 50% had vision 20/200 or worse |
Key Findings
- Radiation retinopathy typically develops 6 months to 3 years after plaque brachytherapy and resembles diabetic retinopathy clinically.
- Reducing radiation dose from 85 Gy to 63 Gy may decrease the incidence and severity of radiation retinopathy without compromising tumor control.
- Custom-designed plaques can minimize radiation exposure to healthy retinal tissue compared to standard-size plaques.
- Genetic tumor profiling allows identification of low metastatic risk tumors, potentially enabling radiation deferral or alternative treatments.
- Investigational systemic therapies such as darovasertib and belzupacap sarotalocan show promise in shrinking tumors or destroying them without radiation.
- Prophylactic intravitreal anti-VEGF injections before clinical onset of retinopathy may improve visual outcomes and reduce retinopathy severity.
Clinical Implications
Clinicians should consider radiation dose reduction and custom plaque design to minimize retinal damage during uveal melanoma treatment. Genetic testing can guide personalized treatment decisions, potentially avoiding unnecessary radiation. Prophylactic intravitreal anti-VEGF therapy represents a promising approach to delay or prevent radiation retinopathy, with ongoing randomized trials expected to clarify its role.
Conclusion
Advances in radiation dosing, tumor genetics, systemic therapies, and prophylactic treatments are reshaping the management of radiation retinopathy, aiming to preserve vision while maintaining effective tumor control in uveal melanoma patients.
References
- Kheir WJ et al. 2022 -- Preliminary results of uveal melanoma treated with iodine-125 plaques
- ClinicalTrials.gov NCT05907954 -- (Neo)Adjuvant IDE196 (darovasertib) in localized ocular melanoma
- ClinicalTrials.gov NCT06007690 -- Phase 3 trial of belzupacap sarotalocan (AU-011) for small choroidal melanoma
- Shields CL et al. 2020 -- Visual outcome after plaque radiotherapy and prophylactic intravitreal bevacizumab
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.